Authors: Blaney, FE Raveglia, LF Artico, M Cavagnera, S Dartois, C Farina, C Grugni, M Gagliardi, S Luttmann, MA Martinelli, M Nadler, GMMG Parini, C Petrillo, P Sarau, HM Scheideler, MA Hay, DWP Giardina, GAM

Citation: Fe. Blaney et al., Stepwise modulation of neurokinin-3 and neurokinin-2 receptor affinity andselectivity in quinoline tachykinin receptor antagonists, J MED CHEM, 44(11), 2001, pp. 1675-1689

Authors: Lightfoot, T Ellis, SW Mahling, J Ackland, MJ Blaney, FE Bijloo, GJ De Groot, MJ Vermeulen, NPE Blackburn, GM Lennard, MS Tucker, GT

Citation: T. Lightfoot et al., Regioselective hydroxylation of debrisoquine by cytochrome P4502D6: implications for active site modelling, XENOBIOTICA, 30(3), 2000, pp. 219-233

Authors: Bromidge, SM Dabbs, S Davies, DT Davies, S Duckworth, DM Forbes, IT Gaster, LM Ham, P Jones, GE King, FD Mulholland, KR Saunders, DV Wyman, PA Blaney, FE Clarke, SE Blackburn, TP Holland, V Kennett, GA Lightowler, S Middlemiss, DN Trail, B Riley, GJ Wood, MD

Citation: Sm. Bromidge et al., Biarylcarbamoylindolines are novel and selective 5-HT2C receptor inverse agonists: Identification of 5-methyl-1-[[2-[(2-methyl-3-pyridyl)oxy]-5-pyridyl]carbamoyl]-6-trifluoromethylindoline (SB-243213) as a potential antidepressant/anxiolytic agent, J MED CHEM, 43(6), 2000, pp. 1123-1134

Authors: Blaney, FE

Citation: Fe. Blaney, Homology modeling and ab initio calculations identify a basis for ligand selectivity for the PPAR gamma nuclear hormone receptor, INT J QUANT, 73(2), 1999, pp. 97-111